Syndax Pharmaceuticals (SNDX) Equity Ratio (2016 - 2026)
Syndax Pharmaceuticals (SNDX) has disclosed Equity Ratio for 12 consecutive years, with 0.09 as the latest value for Q1 2026.
- For Q1 2026, Equity Ratio fell 73.77% year-over-year to 0.09; the TTM value through Mar 2026 reached 0.09, down 73.77%, while the annual FY2025 figure was 0.12, 69.31% down from the prior year.
- Equity Ratio hit 0.09 in Q1 2026 for Syndax Pharmaceuticals, down from 0.12 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.95 in Q1 2023 and bottomed at 0.09 in Q1 2026.
- Average Equity Ratio over 5 years is 0.67, with a median of 0.89 recorded in 2022.
- Year-over-year, Equity Ratio rose 13.13% in 2022 and then tumbled 75.69% in 2025.
- Syndax Pharmaceuticals' Equity Ratio stood at 0.94 in 2022, then decreased by 3.81% to 0.9 in 2023, then plummeted by 56.04% to 0.4 in 2024, then crashed by 69.31% to 0.12 in 2025, then fell by 27.83% to 0.09 in 2026.
- According to Business Quant data, Equity Ratio over the past three periods came in at 0.09, 0.12, and 0.21 for Q1 2026, Q4 2025, and Q3 2025 respectively.